• Publications
  • Influence
Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
Pharmacokinetic studies were performed in ten patients who received short-term (4-15-min) infusions of cisplatin. Computerized nonlinear least-squares analysis (NLIN) and an adapted curve-strippingExpand
Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding.
Toxicity of cisplatin can be decreased by concomitant administration of sodium thiosulfate, which perhaps chemically inactivates this platinum compound. We studied the disappearance of cisplatin andExpand
Pharmacokinetics of carboplatin after i.v. administration.
Pharmacokinetics of the cisplatin analog carboplatin were studied in ovarian cancer patients who received short-term iv infusions of 290-370 mg/m2. Platinum (Pt) was determined by atomic absorptionExpand
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
Pharmacokinetics of cisplatin, spiroplatin, ethylenediaminemalonatoplatinum(II) (JM-40), and carboplatin was studied in BALB/c x DBA/2 F1 mice receiving 10% lethal doses of 15.5, 6.8, 100, and 165Expand
Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.
The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time atExpand
The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
The antitumor agents cisplatin [cis-diamminedichloroplatinum(II), CDDP] and carboplatin [cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), CBDCA] can react with a nucleophilic agent by a directExpand
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
The pharmacokinetics of the novel antipyrimidine agent Brequinar sodium (NSC 368390; DUP 785) was studied in 23 patients with solid tumors during the phase I study of this compound. The drug wasExpand
Pharmacokinetics of carboplatin after intraperitoneal administration
SummaryThe phamacokinetics of carboplatin, ultrafilterable platinum, and total platinum after intraperitoneal (i. p.) administration were studied in peritoneal fluid, plasma, red blood cells (RBCs),Expand
Quantitative determination of cisplatin in body fluids by liquid chromatography with quenched phosphorescence detection.
Cisplatin [CDDP, cis-dichlorodiammineplatinum(II)], which has a high activity towards solid tumours [1], is widely used in anticancer chemotherapy. After administration, cisplatin is rapidly bound toExpand
Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6).
Three groups of 6 rats were treated with cisplatin (3 mg/kg, bolus and 3-h infusion) and spiroplatin (3 mg/kg, bolus) by infusion in the right external jugular vein. The mean amounts of platinum +/-Expand